Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic ...

Regulus Therapeutics will be acquired by Novartis AG for $7 per share in cash. Click here for more information on RGLS ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making ...

At the heart of the acquisition is Regulus’ farabursen, an miRNA-targeting oligonucleotide in early-stage development for ...

Emily DeVito left WNYT in 2022 after five years reporting and anchoring at the station. She's at CDTA. She is in stage 4 kidney failure.

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to ...

Novartis Acquires Regulus Therapeutics in $1.7 Billion Deal for ADPKD Treatment ...

Novartis is set to buy U.S. biotech Regulus Therapeutics for up to $1.7 billion in a move to boost its renal-disease pipeline. The Swiss pharma giant said Wednesday that it would pay Regulus ...

Regulus Therapeutics (Nasdaq: RGLS) saw its shares leap 133% to $7.84 in pre-market activity this morning, on the news it has ...

The transaction, which is expected to close in the second half of 2025, will see Novartis commence a tender offer to purchase all outstanding shares of Regulus at $7 per share in cash at closing.